Table 1

Summary of the treatments.

		First HSCT	CART	Second HSCT
1	Pretreatment HSCT/CART	1. Modified GMALL induction	3. Nilotinib (400 mg) twice daily	4. FLAG-Ida
1	Pretreatment HSCT/CART	1. Modified GMALL induction 2.Hyper-CVAD A/B+imatinib (600 mg) daily	3. Nilotinib (400 mg) twice daily	4. FLAG-Ida 5.Vincristine+dexamethasone+ ponatinib (30 mg) daily
2	Disease status before transplantation	Molecular MRD-negative	NA	Molecular MRD-negative
3	Stem cell source	G-CSF-primed PBSCs	NA	G-CSF-primed PBSCs
4	ABO matching	Major mismatched A+ to O+	Matched A+ to A+	Matched A+ to A+
5	CD34 cell/T cell dose	3.0×10⁶/kg	8.5×10⁶ chimeric T cells	5.06×10⁶/kg
6	CMV IgG status	Both positive	Both positive	Both positive
7	Conditioning regimen	TBI-Cy	Flu-Cy	Flu-Bu (2)
8	GVHD prophylaxis	CSA/MMF	NA	CSA/MMF
9	Maintenance TKI/duration	Imatinib (600 mg) daily/ 2 years	Nilotinib (400 mg) BD/7 months	Ponatinib (30 mg) daily/ 6 months (ongoing)
10	Timeline from the initial diagnosis	5 months	3 years	4 years and 2 months
11	Complications	No GVHD	No CRS	Skin GVHD grade I and catheter-related infection
12	Relapse	Yes 2 years and 6 months later	Yes 8 months later	Yes 9 months later
13	Site of relapse	Bone marrow	Bone marrow	CNS

Abbreviations: Bu, busulfan; CART, chimeric receptor antigen T cells; CMV, cytomegalovirus; CNS, central nervous system; CRS, cytokine release syndrome; CSA, cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine; G-CSF, granulocyte-colony stimulating factor; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; MMF, mycophenolate mofetil; MRD, measurable residual disease; NA, not applicable; PBSC, peripheral blood stem cell; TBI, total body irradiation; TKI, tyrosine kinase inhibitor.

Blood Res 2022;57:158~161 https://doi.org/10.5045/br.2022.2020305